Increase in Bone Mass After One Year of Percutaneous Oestradiol and Testosterone Implants in Postmenopausal Women Who Have Previously Received Long-Term Oral Oestrogens

Savvas, M.; Studd, J. W. W.; Norman, S. G.; Leather, A. T.; Garnett, T; Fogelman, Ignac

doi:10.1097/00006254-199305000-00025

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…described a significant correlation between the serum oestradiol and percentage increase in bone density. Savvas et al 8 . demonstrated an increase in bone mass over a one year period when postmenopausal women who had been given long term oral oestrogen therapy were then given oestradiol implants.…”

Section: Discussionmentioning

confidence: 99%

The effect of long term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy

Wahab

Ballard

Purdie

et al. 1997

BJOG

View full text Add to dashboard Cite

Twelve women who had received oestradiol implantation on demand for at least 15 years following hysterectomy with bilateral oophorectomy, underwent bone densitometry of hip and spine. Bone mass of hip and spine was significantly elevated above that of both the age matched mean to a degree hitherto undocumented. This suggests that oestrogen in high doses or over a long period may produce a true anabolic effect on bone mass.Osteoporosis remains a formidable challenge to medicine, with the prevalence of fracture being augmented by the ageing of the population and the absence of an effective treatment. Future advances are likely to come from the fields of screening and prevention. The principal therapeutic means to retard bone loss in postmenopausal women is oestrogen, although serious doubts remain as to the optimal mode and duration of delivery. Oestrogen decreases the rate of bone resorption, principally by cytokine-mediated inhibition of osteoclastic activity. This leads to the correction of the imbalance between bone resorption and bone formation at bone remodelling sites.Non-oral oestrogens avoid the first pass effect on the liver and allow direct delivery into the systemic circulation'. Transdermal oestrogen can cause skin reactions and compliance is not guaranteed. Percutaneous oestrogen implants which guarantee compliance and are relatively cheap have been used in the prevention and treatment of osteoporosis. There is, however, disagreement as to whether this form of therapy simply arrests bone loss, or whether it also causes a prolonged gain in bone mineral density. Oestradiol has been shown to increase spinal and femoral neck bone mineral density when given in a dose of 75 mg every six months for one year to women with a bone mineral density below the 50th centile2.The use of oestrogen replacement therapy following abdominal hysterectomy and bilateral salpingo-

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of long term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy

Wahab

Ballard

Purdie

et al. 1997

BJOG

View full text Add to dashboard Cite

show abstract

“…Total BMD was increased in postmenopausal women receiving estradiol and testosterone 50‐mg implants every 3 months compared with women receiving estrogen alone (p<0.008), along with significant increases at the vertebrae (p<0.001) and hip (p<0.005) . A small, prospective, randomized study of women receiving estradiol and testosterone implants found a 5.7% increase in spinal BMD and 5.2% in hip BMD (p<0.001) …”

Section: Adverse Effectsmentioning

confidence: 99%

“…47 A small, prospective, randomized study of women receiving estradiol and testosterone implants found a 5.7% increase in spinal BMD and 5.2% in hip BMD (p<0.001). 69 Breast Cancer Several reviews have been published to assess the impact of testosterone on breast cancer development. A review of five testosterone studies in postmenopausal women found inconsistent results of breast cancer risk.…”

Section: Osteoporosismentioning

confidence: 99%

Testosterone Supplementation for Hypoactive Sexual Desire Disorder in Women

2012

View full text Add to dashboard Cite

Over 50% of women are believed to be affected by female sexual dysfunction (FSD). When particularly distressful, FSD is known as hypoactive sexual desire disorder (HSDD). In contrast to male sexual dysfunction that has been extensively researched, there is less evidence addressing the treatment of HSDD in women, particularly with regard to the use of androgen therapy. A variety of testosterone products, including oral, injectable, and transdermal preparations, has been prescribed for the treatment of HSDD in premenopausal women, as well as in those with naturally occurring or surgically induced menopause. Although studies have shown some benefit with testosterone supplementation in women with HSDD, conflicting evidence and debate regarding the clinical efficacy of testosterone remain. Because of concern over potential adverse events, additional studies with longer follow-up periods are necessary before use of testosterone in women with HSDD becomes widespread. Initiation of testosterone therapy must be considered on an individual basis after a thorough discussion with the patient about risks and benefits.

show abstract

Increase in Bone Mass After One Year of Percutaneous Oestradiol and Testosterone Implants in Postmenopausal Women Who Have Previously Received Long-Term Oral Oestrogens

Cited by 2 publications

References 0 publications

The effect of long term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy

The effect of long term oestradiol implantation on bone mineral density in postmenopausal women who have undergone hysterectomy and bilateral oophorectomy

Testosterone Supplementation for Hypoactive Sexual Desire Disorder in Women

Contact Info

Product

Resources

About